Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said ...

s treatment for schizophrenia failed in a study designed ... The trial would have supported a broader approval for the drug.

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia ... of all marketed drugs, and Boehringer adds to a growing list of partners that ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the ... the Cobenfy brand name for the treatment ...

Find out how LB Pharmaceuticals’ LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

At least some of schizophrenia's symptoms are thought ... psychiatrists say—is another question. The drug's list price is more than $22,000 a year compared with roughly $600-$3,200 for a year's ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential.

Psychedelic drugs, such as lysergic acid diethylamide (LSD), can increase neuronal growth, which can have therapeutic effects for conditions such as schizophrenia. However, such drugs can induce ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on ...